You are creating the future of personalized care. Biocept can help.
Explore Partnership Opportunities
Our experience includes working with pharmaceutical companies, major cancer centers, CROs, diagnostic firms and other testing laboratories on projects of various types, including oncological drug development support to assist BioPharma companies in the development of targeted therapies to help patients and healthcare providers in the fight against cancer.
We bring creativity, customization, and responsiveness to all our projects, seeking to best address our clients’ needs and help improve outcomes. We offer superb flexibility when designing and structuring projects.
Our proprietary technologies are focused on cerebrospinal fluid tumor cells (CSF-TCs) and cell-free DNA (cfDNA) biomarker analysis. With expertise in cerebrospinal fluid, Biocept can utilize technologies such as Immunocytochemistry (ICC), Fluorescence In Situ Hybridization (FISH), PCR, and Next Generation Sequencing (NGS) to analyze alterations in both protein and DNA– all from the same sample.
Our technical team is experienced in all aspects of rare cell and cfDNA research and testing, and this core competency allows us to develop collaborations aligned with our clients’ goals and interests.
Contact Antonino Morales, President and CEO, for more information at 858.320.8207 or via email at email@example.com.
Capture More CSF-TCs with Biocept’s Unique Technology
Biocept has developed an advanced method for capturing CSF-TCs from a CSF sample, using a novel microfluidic device and antibody capture cocktail for maximum sensitivity.
Discover the Advantages of Biocept’s CSF-TC Capture Technology
Biocept works with you to customize a CSF-TC capture and analysis protocol that meets your unique needs, including:
- Assay development
- Analysis of established and novel biomarkers
- Patient population profiling
- Correlative science studies
- Patient eligibility / stratification for clinical trials
- Measurement of efficacy endpoints
Who We Work With
- Pharmaceutical and biotechnology companies
- Leading academic research and cancer centers
- Contract research organizations (CROs)
- Diagnostic firms
- Cooperative groups
- Patient advocacy groups